NCT02015013View on ClinicalTrials.gov

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2014

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Idiopathic CD4-PositiveT-Lymphocytopenia

Interventions

BIOLOGICAL

Filgrastim

10 microgram/kg daily for 5 days, Subcutaneous injection.

DRUG

Plerixafor

IV injection 0.24 mg/kg as a single dose, 11 hours prior to apheresis

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02015013 - Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models | Biotech Hunter | Biotech Hunter